The Indolent Natural History of Essential Thrombocythemia: A Challenge to New Drug Development

Tefferi, Ayalew
January 2005
Mayo Clinic Proceedings;Jan2005, Vol. 80 Issue 1, p97
Academic Journal
The article presents information on essential thrombocythemia (ET). This disease was first described in 1934, and subsequently classified as a myeloproliferative disorder in 1951. Evidence-based management currently dictates the use of hydroxyurea in high-risk patients, while drug therapy has not been shown, in a controlled setting, to have an advantage over observation alone in either low-risk or indeterminate-risk patients. The article further discusses the impetus to use drugs other than hydroxyurea in patients with ET and how can one best determine their efficacy.


Related Articles

  • The Clinical Impact of Computed Tomography Immediately Following Primary Chemotherapy in Patients With Epithelial Ovarian Cancer. Whitworth, Jenny M.; Schneider, Kellie E.; Fauci, Janelle M.; Sutton, Amelia L.; Frederick, Peter J.; Bevis, Kerri S.; Straughn Jr., J. Michael; Alvarez, Ronald D. // Clinical Ovarian Cancer;May2010, Vol. 3 Issue 1, p52 

    Purpose: The National Comprehensive Cancer Network recommends computerized tomography (CT) for monitoring patients with epithelial ovarian cancer (EOC) as clinically indicated. We sought to evaluate the impact of the initial post-treatment CT scan on subsequent therapy in patients with EOC....

  • Phase III Trial of Induction Gemcitabine or Paclitaxel Plus Carboplatin Followed by Elective Paclitaxel Consolidation in Ovarian Cancer: Interim Analysis of Induction Chemotherapy. Gordon, Alan N.; Teneriello, Michael; Lim, Peter; Janicek, Mike F.; Burkholder, Tiana L.; Wang, Yanping; Orlando, Mauro; Obasaju, Coleman K.; Gill, John F.; Tai, Datchen F. // Clinical Ovarian Cancer;Nov2009, Vol. 2 Issue 2, p99 

    Background: Combination paclitaxel and carboplatin (TC) is the standard of care for first-line (induction) treatment of ovarian cancer. Gemcitabine plus carboplatin (GC) is approved for recurrent platinum-sensitive ovarian cancer. This trial compared the safety and efficacy of GC and TC...

  • The Long-term Outlook for Essential Thrombocythemia. Campbell, Peter J.; Green, Anthony R. // Mayo Clinic Proceedings;Feb2006, Vol. 81 Issue 2, p157 

    The article discusses the importance of studies on long-term consequences of essential thrombocythemia (ET), a myeloproliferative disorders. Such studies could provide diagnostic work-up and management approaches, comprehensive and complete clinical follow-up, and standardized end point...

  • Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Alvarez-Larrán, A.; Cervantes, F.; Bellosillo, B.; Giralt, M.; Juliá, A.; Hernández-Boluda, J. C.; Bosch, A.; Hernández-Nieto, L.; Clapés, V.; Burgaleta, C.; Salvador, C.; Arellano-Rodrigo, E.; Colomer, D.; Besses, C. // Leukemia (08876924);Jun2007, Vol. 21 Issue 6, p1218 

    The frequency of vascular events and evolution to myelofibrosis (MF) in young individuals with essential thrombocythemia (ET) is not well known. The incidence and predisposing factors to such complications was studied in 126 subjects diagnosed with ET at a median age of 31 years (range:...

  • A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer. Hong Suk Song; Young Rok Do; Heung Moon Chang; Min Hee Ryu; Kyung Hee Lee; Yeul Hong Kim; Dae Sik Hong; Jae Yong Cho; Kyoung Eun Lee; Si Young Kim // Cancer Chemotherapy & Pharmacology;Oct2008, Vol. 62 Issue 5, p763 

    This open-label, multicenter phase II study was conducted to investigate the efficacy and safety of capecitabine plus gemcitabine combination chemotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. We enrolled 63 patients who received capecitabine...

  • Anagrelide: A Review of its Use in the Management of Essential Thrombocythaemia. Wagstaff, Antona J.; Keating, Gillian M. // Drugs;2006, Vol. 66 Issue 1, p111 

    Anagrelide (Agrylin®, Xagrid®) is an oral imidazoquinazoline agent which is indicated in Europe for the reduction of elevated platelet counts in at-risk patients with essential thrombocythaemia who are intolerant of or refractory to their current therapy, and in the US for the reduction of...

  • Lung Clear "Sugar" Cell Tumor and JAK V617F Positive Essential Thrombocythemia: a Simple Coincidence? Yazak, Volkan; Sargin, Gokhan; Yavasoglu, Irfan; Kadikoylu, Gurhan; Tataroglu, Canten; Bozkurt, Gokay; Bolaman, Zahit // Mediterranean Journal of Hematology & Infectious Diseases;2013, Vol. 5 Issue 1, p1 

    The primary clear cell tumor of the lung is an extremely rare benign tumor. This tumor is called "sugar tumor" since clear cell tumor of the lung contains abundant glycogen. We here present a case of lung clear cell tumor of the lung associated to essential thrombocythemia. To the best of our...

  • Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage. Hong, Y.; Wang, G.; del Arroyo, A. Gutierrez; Hernandez, J.; Skene, C.; Erusalimsky, J. D. // Leukemia (08876924);Jun2006, Vol. 20 Issue 6, p1117 

    Anagrelide (ANA) and hydroxycarbamide (HC) are two distinct pharmacological agents used to treat thrombocythaemia associated with myeloproliferative disorders. Although both drugs have been in clinical use for a number of years, comparative studies of their selectivity and mode of action are...

  • The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1. Walz, C.; Chase, A.; Schoch, C.; Weisser, A.; Schlegel, F.; Hochhaus, A.; Fuchs, R.; Schmitt-Gräff, A.; Hehlmann, R.; Cross, N. C. P.; Reiter, A. // Leukemia (08876924);Jun2005, Vol. 19 Issue 6, p1005 

    The 8p11 myeloproliferative syndrome (EMS) also known as stem cell leukemia-lymphoma syndrome (SCLL) is associated with translocations that disrupt FGFR1. The resultant fusion proteins are constitutively active tyrosine kinases, and different FGFR1 fusions are associated with subtly different...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics